Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1855 1
1908 1
1928 1
1944 1
1946 1
1949 1
1951 1
1952 2
1953 1
1955 1
1956 1
1957 1
1962 1
1967 1
1969 1
1970 1
1971 2
1974 3
1975 11
1976 4
1977 5
1978 4
1979 8
1980 2
1981 9
1982 8
1983 13
1984 14
1985 15
1986 6
1987 9
1988 14
1989 16
1990 15
1991 10
1992 18
1993 15
1994 17
1995 14
1996 18
1997 20
1998 20
1999 21
2000 29
2001 31
2002 30
2003 35
2004 44
2005 24
2006 44
2007 41
2008 58
2009 48
2010 64
2011 72
2012 73
2013 73
2014 93
2015 124
2016 121
2017 115
2018 157
2019 159
2020 173
2021 192
2022 190
2023 153
2024 179
2025 59

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,452 results

Results by year

Filters applied: . Clear all
Page 1
Plasma proteomic associations with genetics and health in the UK Biobank.
Sun BB, Chiou J, Traylor M, Benner C, Hsu YH, Richardson TG, Surendran P, Mahajan A, Robins C, Vasquez-Grinnell SG, Hou L, Kvikstad EM, Burren OS, Davitte J, Ferber KL, Gillies CE, Hedman ÅK, Hu S, Lin T, Mikkilineni R, Pendergrass RK, Pickering C, Prins B, Baird D, Chen CY, Ward LD, Deaton AM, Welsh S, Willis CM, Lehner N, Arnold M, Wörheide MA, Suhre K, Kastenmüller G, Sethi A, Cule M, Raj A; Alnylam Human Genetics; AstraZeneca Genomics Initiative; Biogen Biobank Team; Bristol Myers Squibb; Genentech Human Genetics; GlaxoSmithKline Genomic Sciences; Pfizer Integrative Biology; Population Analytics of Janssen Data Sciences; Regeneron Genetics Center; Burkitt-Gray L, Melamud E, Black MH, Fauman EB, Howson JMM, Kang HM, McCarthy MI, Nioi P, Petrovski S, Scott RA, Smith EN, Szalma S, Waterworth DM, Mitnaul LJ, Szustakowski JD, Gibson BW, Miller MR, Whelan CD. Sun BB, et al. Among authors: richardson tg. Nature. 2023 Oct;622(7982):329-338. doi: 10.1038/s41586-023-06592-6. Epub 2023 Oct 4. Nature. 2023. PMID: 37794186 Free PMC article.
Mycoplasma pneumoniae ecephalitis.
Bitnun A, Ford-Jones E, Blaser S, Richardson S. Bitnun A, et al. Among authors: richardson s. Semin Pediatr Infect Dis. 2003 Apr;14(2):96-107. doi: 10.1053/spid.2003.127226. Semin Pediatr Infect Dis. 2003. PMID: 12881797 Review.
The prognosis is guarded with 20 to 60 percent suffering neurologic sequelae. The diagnosis of M. pneumoniae encephalitis should be based on strong evidence of M. pneumoniae infection that includes detection of the organism in culture or using molecular detection te …
The prognosis is guarded with 20 to 60 percent suffering neurologic sequelae. The diagnosis of M. pneumoniae encephalitis should be b …
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Chari A, et al. Among authors: richardson pg. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. N Engl J Med. 2019. PMID: 31433920 Clinical Trial.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD Jr, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC; DETERMINATION Investigators. Richardson PG, et al. N Engl J Med. 2022 Jul 14;387(2):132-147. doi: 10.1056/NEJMoa2204925. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35660812 Free PMC article. Clinical Trial.
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Dimopoulos MA, et al. Among authors: richardson pg. N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762. N Engl J Med. 2018. PMID: 30403938 Clinical Trial.
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P; ELOQUENT-2 Investigators. Lonial S, et al. Among authors: richardson p. N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2. N Engl J Med. 2015. PMID: 26035255 Free article. Clinical Trial.
Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia.
Ushida T, Katayama Y, Hiasa Y, Nishihara M, Tajima F, Katoh S, Tanaka H, Maeda T, Furusawa K, Richardson M, Kakehi Y, Kikumori K, Kuroha M. Ushida T, et al. Among authors: richardson m. Neurology. 2023 Mar 14;100(11):e1193-e1206. doi: 10.1212/WNL.0000000000201709. Epub 2022 Dec 14. Neurology. 2023. PMID: 36517235 Free PMC article. Clinical Trial.
Use of M-M-R II outside of the routinely recommended age range - a systematic literature review.
Pawaskar M, Schmidt E, Marshall GS, Fergie J, Richardson E, Saldutti LP, Li S, Neumann M, Koller L, Kuter B. Pawaskar M, et al. Among authors: richardson e. Hum Vaccin Immunother. 2022 Dec 31;18(1):1-7. doi: 10.1080/21645515.2021.1933874. Epub 2021 Jun 15. Hum Vaccin Immunother. 2022. PMID: 34128759 Free PMC article.
M-M-R(II) (M-M-R II) is routinely used in many countries at 12-15 months with a second dose at 4 to 6 years of age. ...This literature review identified RCTs with evidence to support that M-M-R II is immunogenic and well tolerated in indi …
M-M-R(II) (M-M-R II) is routinely used in many countries at 12-15 months with a second dose at 4 to 6 years of a …
Optomechanical inertial sensors.
Hines A, Richardson L, Wisniewski H, Guzman F. Hines A, et al. Among authors: richardson l. Appl Opt. 2020 Aug 1;59(22):G167-G174. doi: 10.1364/AO.393061. Appl Opt. 2020. PMID: 32749330
Performance simulations for low-frequency gravity-sensitive inertial sensors show attainable acceleration noise floors on the order of 110(-11)m/s(2)Hz. Furthermore, from our performance models, we devised an optimization approach for our sensor designs, sensitivity, and b …
Performance simulations for low-frequency gravity-sensitive inertial sensors show attainable acceleration noise floors on the order of 110(- …
Evaluation of the Safety and Immunogenicity of M-M-RII (Combination Measles-mumps-rubella Vaccine): Clinical Trials of Healthy Children and Adults Published Between 2010 and 2019.
Nyaku M, Richardson E, Martinon-Torres F, Kuter BJ. Nyaku M, et al. Among authors: richardson e. Pediatr Infect Dis J. 2021 Nov 1;40(11):1046-1054. doi: 10.1097/INF.0000000000003273. Pediatr Infect Dis J. 2021. PMID: 34310506
M-M-RII continues to be evaluated as a comparator in clinical trials of other vaccines. Here, we review safety and efficacy data from more recent clinical trials of M-M-RII. METHODS: We performed a systematic literature review of trials using M- …
M-M-RII continues to be evaluated as a comparator in clinical trials of other vaccines. Here, we review safety and efficacy da …
2,452 results